Arvee Laboratories (India) growth ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−18.1%+26.8%−51.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−11.4%+20.5%−64.4%
−19.4%+64.3%−76.3%
+17.7%+104.1%−74.5%
+17.4%+105.3%−74.6%
+13.4%−1.0%−0.3%
+8.1%+7.4%+3.7%
−220.9%−100.6%+179.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ARVEE₹182.00

Arvee Laboratories (India) Limited

· Unclassified
₹ CrorePeersSPCENETGVPTECHMCLNITIRAJASPINWALLJMASINTERCOMMcap ₹201 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-51.4+26.8-18.1—
EBITDA Growth—-64.4+20.5-11.4—
EBIT Growth—-76.3+64.3-19.4—
Net Income Growth—-74.5+104.1+17.7—
EPS Growth—-74.6+105.3+17.4—
Total Assets Growth—-0.3-1.0+13.4—
Total Equity Growth—+3.7+7.4+8.1—
Cash from Operations Growth—+179.2-100.6-220.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.